InflaRx N.V. Common Stock (IFRX) Stock Price Today & Analysis
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
About InflaRx N.V. Common Stock
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
FAQ
- Download the Gotrade app from the App Store or Google Play.
- Create an account and complete KYC.
- Make a deposit.
- Search for the code "IFRX", then tap "Trade".
- Tap the "Buy" button.
- Enter the amount you want to buy. You have two options:
- Buy IFRX by number of shares.
- Buy fractional shares in dollars, starting from $1.
- Swipe up to confirm your order—done!
- Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
- Review revenue and earnings growth.
- Check margins and cash flow.
- Evaluate business outlook and the company's position within its industry.





